Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

PankoMab-GEX (gatipotuzumab)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Glycotope

Drug class:

MUC1 inhibitor

Related drugs:

TA-MUC1 positive	Ovarian Cancer	TA-MUC1 positive	Ovarian Cancer	gatipotuzumab Sensitive: C2 – Inclusion Criteria gatipotuzumab Sensitive : C2	gatipotuzumab Sensitive: C2 – Inclusion Criteria gatipotuzumab Sensitive : C2
TA-MUC1 elevation + EGFR expression	Colorectal Cancer	TA-MUC1 elevation + EGFR expression	Colorectal Cancer	gatipotuzumab + tomuzotuximab Sensitive: C3 – Early Trials gatipotuzumab + tomuzotuximab Sensitive : C3	gatipotuzumab + tomuzotuximab Sensitive: C3 – Early Trials gatipotuzumab + tomuzotuximab Sensitive : C3
TA-MUC1 elevation + EGFR expression	Breast Cancer	TA-MUC1 elevation + EGFR expression	Breast Cancer	gatipotuzumab + tomuzotuximab Sensitive: C3 – Early Trials gatipotuzumab + tomuzotuximab Sensitive : C3	gatipotuzumab + tomuzotuximab Sensitive: C3 – Early Trials gatipotuzumab + tomuzotuximab Sensitive : C3
TA-MUC1 elevation + EGFR expression	Head and Neck Cancer	TA-MUC1 elevation + EGFR expression	Head and Neck Cancer	gatipotuzumab + tomuzotuximab Sensitive: C3 – Early Trials gatipotuzumab + tomuzotuximab Sensitive : C3	gatipotuzumab + tomuzotuximab Sensitive: C3 – Early Trials gatipotuzumab + tomuzotuximab Sensitive : C3
TA-MUC1 elevation + EGFR expression	Non Small Cell Lung Cancer	TA-MUC1 elevation + EGFR expression	Non Small Cell Lung Cancer	gatipotuzumab + tomuzotuximab Sensitive: C3 – Early Trials gatipotuzumab + tomuzotuximab Sensitive : C3	gatipotuzumab + tomuzotuximab Sensitive: C3 – Early Trials gatipotuzumab + tomuzotuximab Sensitive : C3